Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novo Nordisk will begin Phase 3 development of diabetes drug candidate semaglutide, a once-weekly Glucagon-Like Peptide-1 (GLP-1) analogue.
Subscribe to our email newsletter
The diabetes drug candidate successfully completed Phase 2 development in 2010.
Novo Nordisk executive vice president and chief science officer Mads Thomsen said semaglutide represents to further improve type 2 diabetes therapy within the GLP-1 class.
"The clinical data for semaglutide, in terms of glucose control, weight loss and a low level of hypoglycaemic events after weekly dosing, hold great promise for a differentiated profile and improvement to the treatment of patients with type 2 diabetes," Thomsen added.
The company plans to initiate the first Phase 3 study in the SUSTAIN program, which is expected to include more than 8,000 patients, in the first half of 2013.